Miruvor
Sign up
The short answer

What studies of Amitriptyline (Elavil) found

13papers on Amitriptyline (Elavil)
90people in 3 studies testing Amitriptyline (Elavil) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised and studies with no comparison group (very low certainty): 1 of 2 findings is D, a tie, so the grade of overall symptoms, as the rule below says.

2 outcomes rated · see each below

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with Amitriptyline (Elavil). For ME/CFS, Amitriptyline (Elavil) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 13 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Amitriptyline (Elavil) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Amitriptyline (Elavil) · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Pain1 study · 48 people took Amitriptyline (Elavil) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (48 in all).

Studies with no comparison group48 in the study · 3(2–4) months · starting dose 10 mg in 40/48 (83.3%) patients; maximum 25 mg in 26/48 (54.2%) patients, 50 mg 2/48 (4.2%) patients and 75 mg in 1/48 (2.1%) patients

Pain improved.

The evidence is very uncertain about the effect of amitriptyline (Elavil) on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (48 in all)
See the 1 study
  1. Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors. (2022)

    People in the study
    48 in the study
    Dose
    starting dose 10 mg in 40/48 (83.3%) patients; maximum 25 mg in 26/48 (54.2%) patients, 50 mg 2/48 (4.2%) patients and 75 mg in 1/48 (2.1%) patients
    Outcome
    change in the number of headache days
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 41 people took Amitriptyline (Elavil) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 10–20 mg daily

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of amitriptyline (Elavil) on overall symptoms in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)

    People in the study
    108 in the study
    Dose
    10–20 mg daily
    Outcome
    improvement over physical therapy
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
    Selection of participants
    Moderate. comparison group: non-randomised; physical therapy group required receiving physical therapy and not taking medications; medication plus physical therapy classified by medication To be included in the physical therapy group, patients needed to be receiving physical therapy and not taking any of the medications described previously.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: per-arm not analysed not reported; incomplete data for inflammatory markers we had incomplete data for the analysis of inflammatory markers.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome

ME/CFS

Symptoms

Post-exertional malaise1 study · 1 (few people) person took Amitriptyline (Elavil) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · the year subsequent to the Rounds · 3 (25-mg) tablets, every night (few people)

Post-exertional malaise improved.

The evidence is very uncertain about the effect of amitriptyline (Elavil) on post-exertional malaise in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A 56-year-old woman with chronic fatigue syndrome, 1 year later. (1998)

    People in the study
    1 in the study
    Dose
    3 (25-mg) tablets, every night
    Outcome
    only happened a couple of times
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 1 (few people) person took Amitriptyline (Elavil) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · the year subsequent to the Rounds · 3 (25-mg) tablets, every night (few people)

Sleep improved.

The evidence is very uncertain about the effect of amitriptyline (Elavil) on sleep in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A 56-year-old woman with chronic fatigue syndrome, 1 year later. (1998)

    People in the study
    1 in the study
    Dose
    3 (25-mg) tablets, every night
    Outcome
    sleeping better with amitriptyline
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Amitriptyline (Elavil) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · the year subsequent to the Rounds · 3 (25-mg) tablets, every night (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of amitriptyline (Elavil) on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A 56-year-old woman with chronic fatigue syndrome, 1 year later. (1998)

    People in the study
    1 in the study
    Dose
    3 (25-mg) tablets, every night
    Outcome
    walk about a mile now and I also swim
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Amitriptyline (Elavil) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · the year subsequent to the Rounds · 3 (25-mg) tablets, every night (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of amitriptyline (Elavil) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A 56-year-old woman with chronic fatigue syndrome, 1 year later. (1998)

    People in the study
    1 in the study
    Dose
    3 (25-mg) tablets, every night
    Outcome
    much fewer problems than in the past
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of Amitriptyline (Elavil) given together with other treatments looked at. Shown, not graded: they can’t tell what Amitriptyline (Elavil) did alone.

Fatigue Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): Fatigue level (NRS), better (not tested).

Shown, not counted: Amitriptyline (Elavil) was given together with other treatments.

Cognition (brain fog) Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): TMT-A, better (not tested).

Shown, not counted: Amitriptyline (Elavil) was given together with other treatments.

Autonomic symptoms Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): average heart rate (HR) from 2 to 5 min after standing, better.

Shown, not counted: Amitriptyline (Elavil) was given together with other treatments.

Pain Both together

Combination: Plant-based diet + Vitamin C + CBT and psychotherapy + Exercise (unspecified) + Amitriptyline (Elavil) + hochuekkito1 in the study

A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report. (2023): pain, better (not tested).

Shown, not counted: Amitriptyline (Elavil) was given together with other treatments.

Side effects

Stopping because of side effects1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    10 mg at the start

  2. 2Raise

    Raised step by step in 1 of 3 studies

  3. 3Top dose

    Most often 10 mg (2 of 3 studies)

Doses across 3 studies

10 to 10 mg. One study of 108 people went up to 20 mg.

Each study’s dose, as printed

All papers

  1. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.2024 · compared with another group · 108 in the study
    Summary

    This retrospective cohort study asked whether treatments adapted from ME/CFS improve symptoms and inflammatory markers in post–COVID-19 condition at the Miami Veterans Affairs post–COVID-19 clinic. It included 108 patients who started PCC treatments and had at least 2 follow-up visits; the treatment groups were low-dose naltrexone (n = 24; 1.5–4.5 mg daily), amitriptyline (n = 41; 10–20 mg daily), duloxetine (n = 17; 20–120 mg daily), and physical therapy alone (n = 26). Treatment duration was not reported; improvement was defined at least 1 month after starting treatment. Median follow-up was 147 (58–264) days for low-dose naltrexone, 250 (120–310) days for amitriptyline, 174 (36–241) days for duloxetine, and 101 (43–152) days for physical therapy. Improvement in at least 1 of fatigue, pain, brain fog, or dyspnea was reported by 67% taking low-dose naltrexone, 61% taking amitriptyline, 41% receiving physical therapy alone, and 35% taking duloxetine. The adjusted relative hazard of improvement for low-dose naltrexone versus physical therapy alone was 5.04 (95% CI, 1.22–20.77; P = 0.02). Amitriptyline (2.68; 0.80–8.97; P = 0.10) and duloxetine (0.82; 0.17–3.85; P = 0.81) did not significantly improve over physical therapy. Symptom reports: low-dose naltrexone for fatigue and pain; amitriptyline and duloxetine for fatigue; physical therapy for dyspnea and fatigue. The text states low-dose naltrexone decreased C-reactive protein and increased cortisol and other treatments did not, while Table 4 also lists changes for duloxetine; all biomarker changes were nonsignificant (P > 0.05). Harms and withdrawals were not reported.

  2. Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
    Summary

    This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.

  3. Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.2022 · no comparison group · 48 in the study
    Summary

    This observational analytical multicentric retrospective cohort study enrolled 48 patients with post-COVID-19 headache at four third-level university hospitals in Spain. Patients received amitriptyline (AMT); the starting dose was 10 mg in 40/48 (83.3%) patients, and outcomes were assessed between baseline and weeks 8–12. There was no comparison group. The mean reduction in headache days was 9.6 (SD: 10.9; 95% CI 6.5, 12.7) days (p < 0.001). Response rates by weeks 8–12 were 24/48 (50%) for 30% response, 21/48 (43.7%) for 50% response, and 10/48 (21%) for 75% response. The paper also reports statistically significant reductions in intense headache days per month and acute medication days (all p < 0.001). In multivariable regression, history of TTH (B value 10.9, 95% CI 1.3, 20.6, p value: 0.024) and nausea (B value − 8.5, 95% CI − 14.6, − 2.5, p value: 0.007) remained associated with response. Harms: the abstract reports 2/48 (5%) discontinued AMT due to poor tolerability; the results text reports three patients discontinued due to adverse effects, with a retention rate of 95%; Table 3 lists adverse effects in 19/43 (44.18%). The authors state the study lacked a control group, was retrospective, and had a small sample size.

  4. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.2006 · case report · 1 in the study
    Summary

    This case report described one 39-year-old woman with chronic fatigue syndrome and a coexistent major depression episode, admitted to a psychiatric setting. She was given paroxetine 20 mg/day increased to 40 mg/day, and bupropion was added and gradually increased to 450 mg/day; treatment reached full remission after 6 weeks. There was no comparison group. Symptoms, BDI, MADRS and HAM-D were assessed. After 3 weeks, symptoms improved markedly, reaching full remission after 6 weeks; BDI was 22 at baseline and 5 after 6 weeks, MADRS was 25 and 6, and HAM-D was 22 and 6. On follow-up 6 and 12 months later, symptoms were still absent and she could enter a part time job. After an initial boost of energy, she deteriorated slightly. The authors stated that the report is a case and that controlled studies in larger CFS samples are warranted.

  5. On chronic fatigue syndrome.2004 · case report · 1 in the study
  6. A 56-year-old woman with chronic fatigue syndrome, 1 year later.1998 · case report · 1 in the study
    Summary

    This Clinical Crossroads follow-up reported on 1 patient, Ms H, with chronic fatigue syndrome, 1 year after a Medicine Grand Rounds presentation. The patient and her primary physician reported on the year subsequent to the Rounds. She took amitriptyline, 3 (25-mg) tablets every night, and fluoxetine (Prozac), 10 mg in the morning; she also saw a massage therapist weekly, saw a chiropractor, and changed her diet. There was no comparison group. Outcomes were patient and physician reports. Ms H reported sleeping better with amitriptyline, being able to walk about a mile and swim, working full-time all year, and having much fewer problems than in the past; weekend bed rest after stressful times had happened only a couple of times. Her physician reported that about a year later Ms H had improved markedly and had completed a successful year working full-time; Ms H credited amitriptyline for better sleep. Visits to the psychiatrist decreased from weekly to biweekly. Ms H reported that massage helped a lot with chronic tendinitis. She discontinued methylphenidate and venlafaxine. Side effects were not reported. The text did not state limitations.

  7. A patient who recovered from post-COVID myalgic encephalomyelitis/chronic fatigue syndrome: a case report.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes a 55-year-old woman referred to our department for severe fatigue after SARS-CoV-2 infection; her symptoms satisfied the Fukuda case definition of CFS, and the report concerns post-COVID ME/CFS. There was no comparison group, randomisation or blinding reported. She received a multi-component treatment protocol: a vegetable-based diet and ascorbic acid 1000 mg/day; cognitive and behavioral modifications; conditioning exercises; and pharmacotherapy with oral amitriptyline 10 mg before sleep and hochuekkito 7.5 g before every meal. Duration was not reported; treatment was terminated at the sixth visit (21 weeks later). Measured outcomes included fatigue NRS, BFI, TMT-A, axillary temperature, standing heart-rate test and clinical course. The NRS fatigue score decreased from 5 to 0, BFI from 7.0 to 0.5, TMT-A from 45 s to 35 s, and axillary temperature from 37.2 to 36.6. Average HR after standing changed from 99.0 ± 1.2 bpm to 94.3 ± 1.7 bpm (P = 0.015), and change of HR by standing from 15.0 ± 1.2 bpm to 4.3 ± 1.7 bpm (P = 0.002). At 2 weeks fatigue, pain and low-grade fever had started to decrease; at 6 weeks low-grade fever and sensation of heat had disappeared; at 11 weeks fatigue at rest was almost zero; at 21 weeks she could perform activities of daily living without medication and reported complete recovery and return to work as a nurse. Harms, withdrawals and worsening were not reported. The authors state limitations including inability to identify which elements were most effective, possible natural recovery, and incomplete cognitive assessment.

  8. Severe ME in Children.2020 · combination: given with other treatments
    Summary

    The paper presents a series of case reports of individual cases to illustrate clinical presentation and general principles of management of severe paediatric ME/CFS. The author writes that there is very limited data on patients who are very severe, housebound or bedbound. No number of patients, clinic setting, comparison group or formal outcome measures are reported. Treatments described across the cases include nasogastric or nasojejunal tube feeding, intramuscular immunoglobulin monthly for 12 months, amitriptyline, carbamazepine, clarithromycin, doxycycline, opiates, a urinary catheter, active physiotherapy for three months and Tender Loving Care. The paper reports that one case made a very slow recovery, with tube feeding stopped after 3 years, and was operating at 95% of normal 20 years later; another made a full recovery by the end of two years; another recovered completely within 12 months after clarithromycin was changed to doxycycline and had no relapses at follow up 12 years later; and Case A made a full spontaneous recovery. Case B received active physiotherapy for three months, deteriorated further and remained severely affected 20 years later. Case C died. Harms include a traumatic hospital experience, a convulsive myoclonic jerk from noise and sensory overload. The author states that one should not draw too many conclusions from one case.

  9. The expanding potential of low-dose naltrexone in clinical practice with a focus on long COVID.2026 · review
    Summary

    This review examines low-dose naltrexone (LDN) for chronic pain, fibromyalgia, and post-COVID chronic fatigue syndrome/long COVID, noting similarities between long COVID and ME/CFS. It summarizes small studies: in long COVID, Bonilla et al (n=59) reported significant reduction in number of symptoms and FSS scale (P<0.002); Isman et al (n=31) reported mean total SF-36 improved from 36.5 to 24.8 at wk 12 (P<0.0001); Tamariz et al (n=108) reported self-reported improvement 67% with naltrexone, 61% with amitriptyline, and 41% with physical therapy; O’Kelly et al (n=36) reported significant reduction in all symptoms (P<0.05). In fibromyalgia, Abou-Raya et al (n=74) reported VAS change −20.1 with LDN and −10.7 with placebo (P<0.001); Bested et al (n=58) found FIQR difference 1.65 (P=0.3) and SPIR 0.33 (P=0.4); Bruun et al (n=99) found pain intensity change −1.3 with LDN and −0.9 with placebo (P=0.27); Younger et al (n=10) reported self-rated symptoms reduced 32.5% with LDN and 2.5% with placebo (P=0.003). In chronic pain, Beaudette-Zlatanova et al (n=23) found BPI difference −0.3 (P=0.22); Tsui et al (n=45) found no difference in pain severity versus placebo (P=0.55). Reported adverse effects include nausea, sleep disturbances, nightmares, and vivid dreams. No counts of worsening or discontinuation were reported. The authors state evidence is limited by small sample sizes and study design biases.

  10. The role of herbal medicine in supporting cognitive dysfunction associated with long COVID: Review2026 · review
    Summary

    This review examined herbal medicine for cognitive dysfunction associated with Post-COVID-19 Condition (PCC). The search covered PubMed, Scopus, ProQuest, and Cochrane for English-language papers with search parameters between January 2020 and November 2025; five primary clinical studies were included. These were a case study series of 5 patients given EGb761® (Ginkgo biloba); a single case of one 55-year-old female given Hochuekkito with other treatments; a prospective pilot study of 45 participants given Bojungikgi-tang, Kyungok-go, or Cheonwangbosim-dan; a retrospective cohort of 47 patients given Traditional Chinese HMs; and an RCT of 78 participants comparing Triphala with placebo. Durations varied across studies. Outcomes included cognitive severity and cognitive tests, fatigue, respiratory symptoms, emotional distress, oxidative stress, inflammatory biomarkers, and self-report questionnaires. EGb761® appeared to substantially improve cognition in all five patients, with mean time to improvement 10.6 weeks (range 7–16 weeks). The single case reported NRS reducing from 5 to 0 and BFI from 7.0 to 0.5, and TMT-A improving by 10 s. Kim et al. reported no significant between-group cognitive change (p = 0.1225), with 14 participants lost to follow-up. Hsieh et al. reported fatigue and respiratory improvements, but emotional distress changes were not significant. Intakhiao et al. found no significant between-group change in cognitive function; fatigue and headache improved in both groups, and respiratory symptoms were lower than placebo (p = 0.025). No significant adverse events were reported in the Zifko, Kim, or Intakhiao studies. Worsening or stopping was not reported. The authors state the evidence is heterogeneous and methodologically limited.

  11. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  12. Medicinal plants for the management of post-COVID-19 fatigue: A literature review on the role and mechanisms.2025 · review
    Summary

    This narrative review searched PubMed, Embase and Cochrane library databases for studies published until March 2024 on medicinal plants for post-COVID-19 fatigue. The authors summarized six recent studies: one retrospective study, three randomized clinical trial, one prospective study and one case study. The review did not report review-level enrollment, follow-up, side-effect counts or withdrawals. In the retrospective study by Tokumasu et al. involving 102 samples, 71.6 % of patients were prescribed Hochuekkito for general fatigue, the highest frequency of use. In the RCT by Pang et al., 194 out of 388 patients were in the Qingjin Yiqi granules treatment group; after 14 days the QJYQ group's Borg score was 7.89 ± 0.09 and the control group's was 8.37 ± 0.10 (p = 0.026). Karosanisze et al. studied 100 participants, with 50 in the intervention group and 50 in the control group; an herbal combination containing Eleutherococcus, Rhodiola rosea, and Schisandra extracts decreased the duration of post-COVID-19 fatigue with a statistically significant difference between groups. Hawkins et al. reported reduced MFSI fatigue scores after 14 days of essential oil blend inhalation. Teitelbaum et al. reported that of 188 participants given HRG80 red ginseng root powder, 60.1 % felt recovered and 13.3 % described their condition as much better. Oka reported one 55-year-old female given hochuekkito whose numerical rating scale fatigue reduced from 5 to 0 and BFI score dropped from 7.0 to 0.572.

  13. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime